Pharmacotherapy of generalized anxiety disorders has been depended on benzodiazepines for many decades. However, the use of these compounds is restricted because of their adverse effects. Pregabalin is an anticonvulsant indicated as adjunctive therapy for treating adults' partial seizures. It has shown some efficacy in randomized, placebo-controlled clinical trials aimed to treat generalized anxiety disorder. Mechanism of pharmacologic activity of Pregabalin was extensively studied and it was proven to acquire high-affinity binding to α2δ. The current study employed the dark/light box and the elevated plus maze. Male albino mice were allocated into groups: group i: mice received distilled water (16 ml/kg, p.o.), group ii: mice received diazepam (1 mg/kg, p.o.), group iii-iv: mice received a dose of Pregabalin (25 or 50 mg/kg, p.o.), group v: mice treated with rimonabant (1 mg/kg, i.p.) 30 min before a dose of Pregabalin (50 mg/kg), group vi: mice received rimonabant (1 mg/kg, i.p.) 30 min before a dose of distilled water (16 ml/kg, p.o.). Results indicated that Pregabalin (50 mg/kg) showed anxiolytic effect in the two paradigms, the dark/light transition box and the mouse elevated plus maze. Pretreatment with rimonabant diminished most of the anxiolytic effect of Pregabalin (50 mg/kg) as indicated by shorter time spent in white are in the dark/light box and shorter open arm time (%) compared to mice received Pregabalin.
Introduction
Anxiety consists of a diversity of subjective sensations reflecting responses to events or stimuli (Etkin, 2009) . Anxiety is manifested as a number of physical and mental symptoms without logic cause.
Mental symptoms of anxiety include discomfort and apprehension. Anxiety may appear in healthy individuals when show unspecific frightening cues.
There are symptomatic responses to anxiogenic stimuli including tachycardia, dizziness, muscle tension, nausea and chest or abdominal pain.
The symptoms of generalized anxiety disorder (GAD) are physical and psychological. For the psychological part, patients with GAD experiences anxiety and hypervigilance, which refer to the propensity to a mental scan for the environment for anticipating stress factors. Furthermore, people with GAD may startle easily and feel irritable and impatient. Thus, the patient may never be free of worries, that is, negative anticipation of the "next bad thing (fear from fear)."
Pharmacotherapy of GAD has dominated by benzodiazepines for many years. However, use of benzodiazepines is limited nowadays because of the adverse effects which include tolerance, sedation, physical dependence, interaction with other CNS depressants and the development of abstinence syndromes which hinder the chronic use (Woods et al., 1992) . Therefore, research should be dedicated for discovering novel anxiolytics with enhanced adverse-effect profile.
The light/dark transition paradigm depends on that bright illuminated areas are aversive to rodents and on spontaneous exploring of rodents in response to a new environment in which light which act as a mild stressor. The test apparatus is composed of a dark and safe area and an open illuminated aversive area.
Originally, the test was generated for application in male mice. However, the age, strain or weight is critical for this. The magnitude of modifying the exploratory activity relies on the baseline level in the control group of mice. Changes in the type and severity of external stressors contribute to the variability in findings reported by different laboratories.
Further, the light/dark transition paradigm is a test for prediction of anxiolytic-like activity in mice. The recorded transition has been dedicated as an index of activity or exploration because of habituation and the time spent in each part (light or dark areas) are considered as appropriate reflection for aversion. Rickels et al., 2005; Montgomery et al., 2005) and has also shown efficacy in clinical trials for neuropathic pain and fibromyalgia related to postherpetic neuralgia and diabetic neuropathy, respectively (Dworkin et al., 2010; Arnold et al., 2010) . The pharmacologic mechanism of Pregabalin was previously examined in rodents. Studies using series of compounds with structures related to Pregabalin propose that highaffinity binding to α2δ are perfectly predicting anxiolytic action in the Vogel conflict model, which is one of the most predictive assays for screening pharmacological agents with anxiolytic-like properties (Vogel et al., 1971; Belliotti et al., 2005) .
It was previously mentioned that Pregabalin possesses anxiolytic-like action in the mouse elevated plus maze, one animal model of post-traumatic stress disorder and Geller conflict test (Zohar et al., 2008) .
Many receptors are reported to be involved in pain modulation like: cannabinoid type 1 receptors (CB1), 5-HT3 and opioid receptor (Manzanares et al., 2006; Faerber et al., 2007; Mellar and Gavril, 2009 ). CB1
receptors are known to be located in both peripheral and central neurons. The distribution pattern of CB1 receptors is mainly in basal ganglia, hippocampus, cortex and cerebellum within the CNS (Compton et al., 1990) . CB1 receptors are also located in the superficial layers of spinal dorsal horn beside other locations like the the peripheral terminals of primary afferent neurons and within the pain descending pathway (Svizenska et al., 2008) . Some CB1 receptors are located in peripheral and central nerve terminals. When they are activated, they modulate the release of inhibitory and excitatory neurotransmitters.
It remains for elucidation whether the interaction of
Pregabalin with voltage activated Ca ++ channels is sufficient to explain the broad clinical spectrum (Sills, 2006) . Little is known about the possible involvement of CB1 activation in the anxiolytic effect of Pregabalin, the present work aimed to determine whether the anxiolytic action of Pregabalin in two behavioral paradigms for mice involves activation of CB1 receptors.
Materials and methods

Animals
All experimental protocols were approved by the 
Experimental design
Mice were randomly divided into two experiments.
Mice were randomly allocated for the EPM test and classified into different groups (n = 6 mice per group). 
Experiment I
Experiment II
Mice were assigned in the following groups as:
Rimonabant (1 mg/kg, i.p.) + Pregabalin (50 mg/kg) group. In addition, control groups were assigned as following to help eliminate any effect for the drug vehicles. However, data taken from these groups were not shown in illustrations. Double vehicle group (DMSO + distilled water) and DMSO+ Pregabalin (50 mg/kg) group were used for excluding any pharmacological activity of the solvents.
For determination of the per se effect of each receptor agonist/antagonist the following group was assigned as, rimonabant+ distilled water in the same aforementioned doses. In another set of the experiment, mice were assigned for the light-dark box. In general, Pregabalin (or distilled water) was administered by oral gavage however; rimonabant was given by intraperitoneal injection.
Justification of doses
Doses of Pregabalin were selected based on previous studies (Eutamene et al., 2000) given 30 min before the second one and, mice were tested in the EPM after 30 min.
Behavioral assessment
Mice were utilized for each of the following experiments; each experiment was done separately.
Dark-light transition box
The test relies on that illuminated bright areas are aversive to rodents and on the exploration done by mice that occurs spontaneously in reaction to mild stressful conditions in novel environment and in light compartments (Crawley and Goodwin, 1980 (File, 1992; De Vry et al., 1993) .
The test depends on the initial rodent paradigm created by Crawley and Goodwin (1980) , scientists usually use it with many reported modifications to the structure. Thus, the light/dark test is useful to predict either the anxiolytic-like or anxiogenic-like activity of drugs. It acquires some unique properties like easy to apply and quick, without the necessary pre-training for animals, there is no food or water deprivation and that natural stimulus is employed.
The process of transition has been utilized as an index of exploratory activity because of habituation while time spent in each of the two compartments reflects aversion (Belzung et al., 1987) . Indeed, it is superior to measure to the percent of time spent and the movements/exploratory behavior in each compartment (Hascoet and Bourin, 1998 (Lister, 1990; Griebel, 1996) .
Elevated plus maze
The maze is a commonly utilized test for unconditioned anxiety, first developed by File and collaberators (Pellow et al., 1985) . This apparatus is within the open sides). However, amelioration of total arm entries or in the number of entries into closed arms refers to non-specific effects for the drug on the motor function (Carobrez and Bertoglio, 2005) . The reliability and sensitivity of this test increases when using more detailed approaches to analyze rodent behavior on the EPM, such as determining the risk assessment behavior (Weiss et al., 1998) . Patients with anxiety can also display fear from open spaces and high places, and may even display thigmotaxis and risk assessment under these conditions and this point to some degree of homology (Rodgers et al., 1997) .
The testing paradigm was designed as previously introduced by Lister (1987) was excluded from the group data. 
Statistical Analysis and data manipulation
Results
Data documented that treatment with diazepam (1 mg/kg) or Pregabalin (50 mg/kg) in mice produced significant changes in anxiety behavior in 2 well documented models of anxiety. 
Discussion
One difficulty during testing anxiety disorders in experimental studies is the lack of concrete undergoing a test for anxiety (Ohl, 2005) . The results showed that Pregabalin possessed anxiolytic-like activity in elevated plus maze and mouse light/dark tests. These results came convenient with those obtained previously (Field et al., 2001; Zohar et al., 2008) . These authors discovered that Pregabalin exerted anxiolytic activity in rat conflict, elevated plus maze and coustic startile response tests.
Furthermore, Pregabalin exhibits anxiolytic activity in previous clinical studies (Frampton and Foster, 2006; Pande et al., 2004) .
The mechanism of the anxiolytic activity of Pregabalin is not fully determined and little data are available about the role of CB1 receptors in the anxiolytic mechanism of Pregabalin. However, there are many evidences about the role of CB1 receptors in anxiety. In the CNS, adenosine acts primarily as an inhibitory neuromodulator, exhibits many behavioral responses (Barraco, 1991) .
In light/dark test for the first time to demonstrate the anxiolytic effect of Pregabalin in mice and the role of cannabinoid receptors. However, the pretreatment Pregabalin was reported to produce ataxia and decrease locomotor function at doses that are 10-30fold greater than those active to control seizures.
Results suggest that anticonvulsant action of
Pregabalin is different in mechanism from the prototype antiepileptic medications and similar to gabapentin. Findings highlight that Pregabalin has many properties that make it superior in treating human partial seizures. Greater dosages (ED50 = 31 mg/kg), Pregabalin was reported to prevent clonic seizures in mouse pentylenetetrazole model (Vartanian et al., 2006) . Additional experiments will be required to demonstrate the relevance of these effects in vivo.
In rat hippocampus in vivo, both Pregabalin and gabapentin caused electrophysiological changes different from those of a GABAA positive modulator, a GABA uptake blocker or a GABA degradation inhibitor (Stringer and Aribi, 2002; Stringer and Taylor, 2000) . Therefore, neither Pregabalin nor gabapentin appears to be GABAmimetic or enhancers for the pharmacological action, suggesting that GABA effects do not account for their pharmacological activity.
The initial chemical synthesis that discovered Pregabalin was relying on altering inhibitory synaptic activity in brain by interacting with GABA synthetic enzymes in brain such as glutamic acid decarboxylase, which is the primary GABA synthetic enzyme. Although gabapentin and Pregabalin were reported to augment the activity of glutamic acid decarboxylase in vitro (Silverman et al., 1991) , one subsequent study with rat brain showed that neither gabapentin nor Pregabalin altered concentration of GABA in brain tissues (Errante and Petroff, 2003) , while the known GABA transaminase inhibitor, vigabatrin, increased brain GABA levels. In vitro,
Pregabalin and gabapentin did not inhibit GABA transport like the known GABA uptake inhibitor, tiagabine (Su et al., 2005) .
Conclusion
The current study provided some evidence that CB1 receptors-mediated response account for the anxiolytic-like effect of Pregabalin. Further studies are needed to support the present findings in other models of anxiety in rodents beside important confirmatory ligand binding assays.
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